Access Statistics for Tomas Philipson

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Adjusting Measures of Economic Output for Health: Is the Business Cycle Countercyclical? 0 0 0 0 0 2 6 8
Adjusting National Accounting for Health: Is the Business Cycle Countercyclical? 0 0 0 62 0 2 13 103
Aging and the Growth of Long-Term Care 0 1 1 31 0 2 8 152
Aging and the Growth of Long-Term Care 0 0 0 243 0 1 22 1,315
An Economic Evaluation of the War on Cancer 0 0 0 97 0 1 14 375
An Empirical Examination of Information Barriers to Trade in Insurance 1 1 1 1 2 2 17 1,065
An Empirical Examination of Information Barriers to Trade in Insurance 0 0 0 420 0 1 43 2,673
Antitrust and the Not-For-Profit Sector 0 0 0 321 0 0 10 1,058
Antitrust in the Not-For-Profit Sector 0 0 0 173 0 2 13 793
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process 0 0 0 86 0 0 5 512
Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts 0 0 0 0 0 1 10 15
Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts 0 0 0 77 0 1 12 270
Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets 0 0 0 37 0 1 14 128
Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets 0 0 0 0 0 0 8 9
Consumption vs. Production of Insurance 0 0 0 108 0 1 13 778
Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts 0 0 1 2 0 0 17 22
Data MArkets and OPtimal Sample Size Determination 0 0 0 0 0 0 9 2,844
Death, Tetanus and Aerobics: The Evaluation of Disease-Specific Health Interventions 0 0 0 49 0 0 7 464
Death, tetanus, and aerobics: The evaluation of disease-specific health interventions 0 0 0 11 0 0 6 221
Disease Complementarities and the Evaluation of Public Health Interventions 0 0 0 124 0 0 5 907
Disease Eradication: Private vs. Public Vaccination 0 0 0 0 0 1 7 575
Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension 0 0 0 48 0 3 10 139
Economic Epidemiology and Infectious Diseases 0 0 0 918 0 3 15 2,757
Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption 0 0 0 57 0 1 8 311
Estimating the Extent of Trade Under Incomplete Information: The Case of HIV 0 0 0 0 0 0 6 139
External Treatment Effects and Program Implementation Bias 0 0 0 76 0 0 9 552
External Treatment Effects and Program Implementation Bias 0 0 0 15 0 1 7 113
Financial Health Economics 0 0 0 145 0 1 18 366
Health Care Adherence and Personalized Medicine 0 0 0 66 0 1 18 89
Health Care, Technological Change, and Altruistic Consumption Externalities 0 0 0 48 0 0 11 383
Health investment complementarities under competing risks 0 0 1 214 0 8 17 1,195
How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations 0 0 1 92 0 1 16 83
Integrated Insurance Design in the Presence of Multiple Medical Technologies 0 0 0 23 0 0 6 176
Intellectual Property & External Consumption Effects: Generalizations From Health Care Markets 0 0 0 0 0 0 7 11
Intellectual Property & External Consumption Effects: Generalizations From Health Care Markets 0 0 0 1 0 0 9 12
Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets 0 0 0 151 0 2 12 571
Intellectual Property and Marketing 0 0 0 91 0 1 17 409
Intellectual Property and Marketing 0 0 0 0 0 1 10 16
International Health Economics 0 0 0 0 0 1 7 10
International Health Economics 0 0 0 47 0 0 6 88
Is Health Care Technology Over-Approved? A Meta-Analysis of Revealed Preference 0 0 0 0 2 2 3 183
Is the Food and Drug Administration Safe and Effective? 0 0 0 1 0 1 9 13
Is the Food and Drug Administration Safe and Effective? 0 0 0 78 0 2 14 288
Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity 0 0 1 407 1 2 15 1,277
Merit Motives & Government Intervention: Public Finance in Reverse 0 0 0 123 0 0 14 639
Merit Motives and Government Intervention: Public Finance in Reverse 0 0 1 125 1 2 21 1,171
Merit Motives and Government Intervention: Public Finance in Reverse 0 0 1 204 0 1 7 869
Mortality Contingent Claims, Health Care, and Social Insurance 0 0 0 2 1 3 8 1,180
Mortality Contingent Claims, Health Care, and Social Insurance 0 0 0 162 0 1 8 606
Nonprofit Production 0 0 0 0 0 0 8 204
Nonprofit Production and Competition 0 0 1 301 1 7 18 1,274
Observational Agency and Supply-Side Econometrics 0 0 0 28 0 0 6 395
Pricing and R&D with Related Margins 0 0 0 0 0 0 8 571
Public Liabilities and Health Care Policy 0 0 0 32 0 0 6 106
Rational Epidemics and their Public Control 0 0 0 0 0 1 14 646
Self-Interested Treatment Evaluation in Experiments 0 0 0 0 0 0 8 118
Sharing R&D Risk in Healthcare via FDA Hedges 0 0 2 30 0 1 21 114
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures 0 0 0 72 1 1 21 399
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures 0 0 1 106 0 1 8 670
Terminal Care and The Value of Life Near Its End 0 1 3 213 0 1 19 716
The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry 0 0 0 283 0 1 9 956
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in The US Pharmaceuticals Industry 0 0 0 0 1 1 9 14
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US 0 0 1 38 0 1 12 147
The Economic Value of Eliminating Cancer 0 6 19 19 0 9 20 20
The Effects of Product Liability Exemption in the Presence of the FDA 0 0 0 19 0 0 7 203
The Future of Old-Age Longevity: Competitive Pricing of Morality Contingent Claims 0 0 0 0 0 0 7 1,005
The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims 0 0 0 68 0 2 4 349
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 0 0 0 89 0 1 15 387
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 0 0 0 0 0 0 14 19
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 0 0 0 492 0 0 19 1,622
The Impact of Comparative Effectiveness Research on Health and Health Care Spending 0 0 0 57 0 2 11 240
The Long-Run Growth in Obesity as a Function of Technological Change 0 0 1 90 0 3 14 357
The Long-Run Growth in Obesity as a Function of Technological Change 1 1 2 596 1 3 11 2,287
The Private Demand for Information and the Effects of Public Testing Programs: The Case of HIV 0 0 0 0 0 1 2 459
The Quantity and Quality of Life and the Evolution of World Inequality 0 0 0 919 0 0 20 2,714
The Rise in Old Age Longevity and the Market for Long-Term Care 0 0 0 3 0 1 8 779
The Rise in Old Age Longevity and the Market for Long-Term Care 0 0 0 234 0 1 12 1,788
The Value of Life Near its End and Terminal Care 0 0 1 268 0 4 21 782
The Value of Life Near its End and Terminal Care 0 0 0 230 0 0 6 455
The Value of Life in General Equilibrium 0 0 0 92 0 0 20 371
Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs 0 0 0 136 1 2 17 617
Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS 0 0 0 1 0 0 6 270
Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS 0 0 0 40 0 1 7 316
Total Working Papers 2 10 39 9,392 12 101 975 49,303

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies 0 0 0 57 0 0 15 231
A Reexamination of the Costs of Medical R&D Regulation 0 0 1 14 0 0 10 78
A Theoretical and Empirical Investigation of the Effects of Public Health Subsidies for STD Testing 0 0 1 136 0 1 9 462
Altruism and Innovation in Health Care 0 0 0 21 2 2 13 151
An Empirical Examination of Information Barriers to Trade in Insurance 0 0 0 222 0 0 21 973
An economic evaluation of the war on cancer 0 0 2 110 0 0 14 596
An empirical examination of the implications of assortative matching on the incidence of HIV 0 0 0 39 0 1 7 94
Antitrust in the Not-for-Profit Sector 0 0 0 114 0 0 15 472
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process 0 1 1 30 2 5 17 321
Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital? 0 0 0 35 0 0 12 191
Commentary 0 0 0 2 1 1 3 11
Commentary 0 0 0 2 0 1 4 17
Commentary 0 0 0 3 0 1 6 32
Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts 0 0 1 147 0 4 31 757
Cost-effectiveness analysis and innovation 0 0 0 112 1 1 16 435
Data Markets and the Production of Surveys 0 0 0 23 0 0 7 113
Data Markets, Missing Data, and Incentive Pay 0 0 0 0 0 0 8 190
Defining Value: The Need for a Longer, Broader View 0 0 0 15 0 0 8 69
Desegregation and Social Monopoly Pricing 0 0 0 2 0 1 4 9
Disease Eradication: Private versus Public Vaccination 0 1 9 424 2 4 34 1,080
Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets 0 0 0 40 1 3 15 185
Dynamic information release 0 0 0 3 0 1 7 20
Endogenous cost-effectiveness analysis and health care technology adoption 0 0 0 18 0 0 5 115
Equilibrium and Efficiency in an Organized Vote Market 0 0 0 0 0 0 12 250
Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA 0 0 0 3 2 3 13 33
Evaluating an Argument for Affirmative Action 0 0 0 3 0 1 6 18
External Costs of Risky Health Behaviors Associated with Leading Actual Causes of Death in the U.S.: A Review of the Evidence and Implications for Future Research 0 0 1 1 0 0 6 11
Financial Health Economics 0 0 0 47 1 1 15 199
Geographic Variation in Health Care: The Role of Private Markets 1 1 1 76 1 2 13 433
HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH 0 0 0 2 1 1 9 33
How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations 0 0 0 14 1 1 12 58
How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations 0 0 1 10 0 5 20 76
Integrated Insurance Design in the Presence of Multiple Medical Technologies 0 0 0 23 0 0 11 256
Is the Food And Drug Administration Safe And Effective? 0 0 0 21 0 0 6 331
Is the Obesity Epidemic a Public Health Problem? A Review of Zoltan J. Acs and Alan Lyles's Obesity, Business and Public Policy 0 0 0 27 0 2 18 406
Labor Markets in Statistics: The Subject Supply Effect in Medical R&D 0 0 0 2 1 2 8 35
Labor Supply and Weight 0 0 1 51 0 1 20 159
Longevity Complementarities under Competing Risks 0 0 2 167 0 1 17 569
Managed Care and the Quality of Health Care: A Misguided Debate? 0 0 0 0 0 0 3 234
Measurement errors: A principal investigator-agent approach 0 0 0 38 0 1 2 127
Multiple-output agency incentives in data production: experimental evidence 0 0 0 12 1 1 6 64
Old-Age Longevity and Mortality-Contingent Claims 0 1 4 322 0 2 18 865
Pricing and R&D When Consumption Affects Longevity 0 0 0 0 0 0 5 204
Private Vaccination and Public Health: An Empirical Examination for U.S. Measles 0 0 0 44 0 0 11 177
Public Financing and the Market for Long-Term Care 0 0 0 24 0 0 8 107
Public Spending on AIDS Education: An Economic Analysis 0 0 0 5 0 1 6 251
Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection 0 0 0 41 0 0 10 165
Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors 0 0 0 10 0 3 8 76
RESPONSE TO EPSTEIN'S COMMENT ON “HETEROGENEITY IN ACTION” 0 0 0 1 1 3 17 35
Rational Epidemics and Their Public Control 0 0 0 1 0 3 28 713
Sharing R&D Risk in Healthcare via FDA Hedges 0 1 1 4 1 3 16 25
Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&D for Neglected Diseases 0 0 0 7 0 1 7 48
Social Welfare and Measurement of Segregation 0 0 0 71 1 1 9 153
Subject Evaluation in Social Experiments 0 0 0 0 0 1 11 383
The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 0 0 0 72 0 1 14 310
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry 0 0 1 32 0 1 13 297
The Economic Epidemiology of Crime 0 0 0 46 0 0 8 1,104
The Impact of Public Testing for Human Immunodeficiency Virus 0 0 2 37 0 0 5 104
The Option Value of Innovation 0 1 1 47 0 2 6 221
The Quantity and Quality of Life and the Evolution of World Inequality 1 1 5 720 2 7 63 2,426
The Regulation of Medical Innovation and Pharmaceutical Markets 0 0 1 11 0 0 4 30
The Responsiveness of the Demand for Condoms to the Local Prevalence of AIDS 0 0 0 31 0 1 15 180
The Rise in Old-Age Longevity and the Market for Long-Term Care 0 0 0 106 1 1 16 460
The Value of Diagnostic Testing in Personalized Medicine 0 0 1 61 0 0 6 230
The evaluation of new health care technology: The labor economics of statistics 0 0 0 70 1 1 8 365
The growth of obesity and technological change 0 0 0 32 0 2 33 169
The impact of comparative effectiveness research on health and health care spending 0 0 0 35 0 2 15 290
The institute of medicine report on the FDA: where is the science? 0 0 0 26 1 1 12 152
The nonprofit sector and industry performance 0 2 5 261 2 6 36 743
The welfare loss of disease and the theory of taxation 0 0 0 54 1 2 10 151
The world‐wide growth in obesity: an economic research agenda 0 0 0 9 1 3 10 649
Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA 0 0 0 26 0 0 9 110
Welfare-Enhancing Technological Change and the Growth of Obesity 0 0 0 152 0 0 14 443
Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs 0 0 0 115 4 7 44 658
`Me-Too' Innovation in Pharmaceutical Markets 0 0 0 79 0 7 14 308
`RATIONAL CHOICE, PUBLIC POLICY AND AIDS' 0 0 0 0 2 3 6 8
Total Journal Articles 2 9 42 4,618 35 113 993 22,504

Book File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Health and Wealth Disparities in the United States 0 0 0 6 0 1 10 44
Total Books 0 0 0 6 0 1 10 44

Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
"Me-Too" Innovation in Pharmaceutical Markets 0 0 0 0 0 3 14 280
A direct test of the 'lemons' model: the market for used pickup trucks 0 0 1 15 1 2 10 74
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process 0 0 0 0 0 14 39 176
Asymmetric Information and the Not-for-Profit Sector Does Its Output Sell a a Premium? 0 0 0 19 0 0 7 72
Economic epidemiology and infectious diseases 1 2 4 957 3 8 32 3,015
Economics of Obesity 0 0 3 28 0 3 14 105
Economics of Obesity 0 1 1 38 0 1 11 110
Medical Care Output and Productivity in the Nonprofit Sector 0 0 0 12 0 0 10 73
Public Financing and the Market for Long-Term Care 0 0 0 8 0 0 9 61
The Economic Value and Pricing of Personalized Medicine 0 0 0 27 2 2 8 85
The Effects of Product Liability Exemption in the Presence of the FDA 0 0 0 24 0 1 13 144
Theories of Firm Behavior in the Nonprofit Sector. A Synthesis and Empirical Evaluation 0 0 0 147 0 2 14 438
Total Chapters 1 3 9 1,275 6 36 181 4,633

logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage statistics for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Örebro University School of Business.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Since October 2025, abstract view statistics are potentially heavily influenced by traffic from AI bots and tools that we could not eliminate despite our best efforts.

Statistics updated 2026-08-07